{"prompt": "['Alliance A221504', '51. Maher DP, Wong W, White PF, et al. Association of increased postoperative opioid administration with', 'non-small-cell lung cancer recurrence: a retrospective analysis. Br J Anaesth. 2014;113 Suppl 1:i88-', '94.', '52. Moss J, Singleton PA, Barrett A, Johnson L. Effect of methylnaltrexone on disease progression rate in', 'advanced illness patients with cancer. Annual Meeting of the American Society of Anesthesiologists:', 'www.asaabstracts.com; 2015:Abstr 4032.', '53. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al. Prostate-specific antigen and pain surrogacy', 'analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007;25(25):3965-3970.', '54. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate', 'cancer. N Engl J Med. 2011;364(21): 1995-2005.', '55. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic', 'castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.', 'Lancet. 2010;376(9747):1147-1154.', '56. Halabi S, Vogelzang NJ, Kornblith AB, et al. Pain predicts overall survival in men with metastatic', 'castration-refractory prostate cancer. J Clin Oncol. 2008;26(15):2544-2549.', '57. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for', 'advanced prostate cancer. N Engl J Med.', '58. Herndon JE, 2nd, Fleishman S, Kornblith AB, Kosty M, Green MR, Holland J. Is quality of life', 'predictive of the survival of patients with advanced nonsmall cell lung carcinoma? Cancer.', '1999;85(2):333-340.', '59. Quinten C, Coens C, Mauer M, et al. Baseline quality of life as a prognostic indicator of survival: a', 'meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol. 2009;10(9):865-', '871.', '60. Siemens W, Gaertner J, Becker G. Advances in pharmacotherapy for opioid-induced constipation - a', 'systematic review. Expert Opin Pharmacother. 2015;16(4):515-532.', '61. Slatkin N, Thomas J, Lipman AG, et al. Methylnaltrexone for treatment of opioid-induced constipation', 'in advanced illness patients. J Support Oncol. 2009;7(1):39-46.', '62. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced', 'illness. N Engl J Med.2008;358(22):2332-2343.', '63. Gottfridsson C, Carlson G, Lappalainen J, Sostek M. Evaluation of the effect of Naloxegol on cardiac', 'repolarization: a randomized, placebo- and positive-controlled crossover thorough QT/QTc study in', 'healthy volunteers. Clin Ther. 2013;35(12): 1876-1883.', '64. Webster L, Chey WD, Tack J, Lappalainen J, Diva U, Sostek M. Randomised clinical trial: the long-', 'term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation. Aliment', 'Pharmacol Ther. 2014;40(7):771-779.', '65. Anon. Schedules of controlled substances: removal of naloxegol from control. Final rule. Fed Regist.', '2015;80(15):3468-3470.', '66. Sloan JA, Liu H, Sargent DJ, et al. A patient-level pooled analysis of the prognostic significance of', 'baseline fatigue for overall survival (OS) among 3,915 patients participating in 43 North Central Cancer', 'Treatment Group (NCCTG) and Mayo Clinic Cancer Center (MC) oncology clinical trials. J Clin', 'Oncol.2009;27(15S):abstr9599.', '67. Tan AD, Novotny PJ, Kaur JS, et al. A patient-level meta-analytic investigation of the prognostic', 'significance of baseline quality of life (QOL) for overall survival (OS) among 3,704 patients', '60', 'Update 2', 'Version Date 6/25/2019']['Alliance A221504', 'participating in 24 North Central Cancer Treatment Group (NCCTG) and Mayo Clinic Cancer Center', '(MC) oncology clinical trials. J Clin Oncol. 2008;26(15S):abstr9515', '68. Ardizzoni A, Tiseo M, Boni L, et al. Pemetrexed versus pemetrexed and carboplatin as second-line', 'chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized', 'phase II study and pooled analysis with the NVALT7 trial. J Clin Oncol. 2012;30(36):4501-4507.', '69. Zukin M, Barrios CH, Pereira JR, et al. Randomized phase III trial of single-agent pemetrexed versus', 'carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern', 'Cooperative Oncology Group performance status of 2. J Clin Oncol. 2013;31(23):2849-2853.', '70.', 'Patel JD, Socinski MA, Garon EB, et al. PointBreak: a randomized phase III study of pemetrexed plus', 'carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel', 'plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or', 'IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31(34):4349-4357.', '71. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in', 'patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327-', '3334.', '72. Barlesi F, Scherpereel A, Rittmeyer A, et al. Randomized phase III trial of maintenance bevacizumab', 'with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in', 'advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol.', '2013;31(24):3004-3011.', '73. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-', 'cell lung cancer. N Engl J Med. 2006;355(24):2542-2550', '74. Stinchcombe TE, Cella D. Does maintenance pemetrexed maintain quality of life? Lancet Oncol.', '2012;13(3):224-225', '75. Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the', 'Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer.', '1995;12(3):199-220', '76. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development', 'and validation of the general measure. J Clin Oncol. 1993;11(3):570-579.', '77. Basch E, Jia X, Heller G, et al. Adverse symptom event reporting by patients VS clinicians: relationships', 'with clinical outcomes. J Natl Cancer Inst. 2009;101(23):1624-1632.', '78. Camilleri M, Rothman M, Ho KF, Etropolski M. Validation of a bowel function diary for assessing', 'opioid-induced constipation. Am J Gastroenterol. 2011;106(3):497-506.', '79. Zinner RG, Fossella FV, Gladish GW, et al. Phase II study of pemetrexed in combination with', 'carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer.', '2005;104(11):2449-2456.', '80. Vang D, Paul JA, Nguyen J, et al. Small-molecule nociceptin receptor agonist ameliorates mast cell', 'activation and pain in sickle mice. Haematologica. 2015;100(12):1517-1525.', '81. Kohli DR, Li Y, Khasabov SG, et al. Pain-related behaviors and neurochemical alterations in mice', 'expressing sickle hemoglobin: modulation by cannabinoids. Blood. 2010;116(3):456-465.', '82. Vergis R, Corbishley CM, Norman AR, et al. Intrinsic markers of tumour hypoxia and angiogenesis in', 'localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised', 'radiotherapy trials and one surgical cohort study. Lancet Oncol. 2008;9(4):342-351.', '61', 'Update 2', 'Version Date 6/25/2019']\n\n###\n\n", "completion": "END"}